We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00423189
Recruitment Status : Terminated (Lack of efficacy)
First Posted : January 18, 2007
Results First Posted : March 4, 2016
Last Update Posted : March 4, 2016
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Age-Related Macular Degeneration
Interventions: Drug: Ranibizumab (Lucentis)
Drug: 0.5mg ranibizumab

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
7 patients, over a 12 month period were followed after receiving treatment of either decreased fluence(2 different fluences) and 0.5mg ranibizumab, as compared to monotherapy of 0.5mg ranibizumab at a single site

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
patients that were considered to have recalcitrant wet age related macular degeneration were recruited for this trial

Reporting Groups
Ranibizumab Only drug - intravitreal ranibizumab
Ranibizumab and 40% Fluence PDT(Procedure) 40% fluence photodynamic therapy - procedure
Ranibizumab and 20% Fluence PDT(Procedure) 20% fluence photodynamic therapy - procedure

Participant Flow:   Overall Study
    Ranibizumab Only   Ranibizumab and 40% Fluence PDT(Procedure)   Ranibizumab and 20% Fluence PDT(Procedure)
STARTED   2   3   2 
COMPLETED   2   2   2 
NOT COMPLETED   0   1   0 
Death                0                1                0 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Arm 1 drug - intravitreal ranibizumab
Arm 2 40% fluence photodynamic therapy - procedure
Arm 3 20% fluence photodynamic therapy - procedure
Total Total of all reporting groups

Baseline Measures
   Arm 1   Arm 2   Arm 3   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   3   2   7 
[Units: Years]
Mean (Standard Deviation)
 73  (3)   78  (7)   67  (5)   72  (5) 
[Units: Participants]
Female   0   0   0   0 
Male   2   3   2   7 
Region of Enrollment 
[Units: Participants]
United States   2   03   2   7 

  Outcome Measures

1.  Primary:   Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of >15 Letters at 12 Months)   [ Time Frame: 1 Year ]

2.  Secondary:   Number of Intravitreal Injections With Ranibizumab Needed by Patients at 12 Months   [ Time Frame: 1 Year ]

3.  Secondary:   OCT 3 Macular Thickness Improvement (Baseline-1month, 2months, 3months, 6months &12 Months)   [ Time Frame: 1 Year ]

4.  Secondary:   Choroidal Perfusion as Assessed by ICG Angiography at 1, 2, 3, 6, and 12 Months   [ Time Frame: 1 Year ]

5.  Secondary:   Safety of Combination Therapy With Verteporfin PDT and ITV Ranibizumab   [ Time Frame: 1 Year ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The trial was discontinued due to a lack of efficacy.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: David M. Brown
Organization: Retina Consultants of Houston
phone: 713-524-3434
e-mail: dmbmd@houstonretina.com


Responsible Party: David M. Brown, M.D., Greater Houston Retina Research
ClinicalTrials.gov Identifier: NCT00423189     History of Changes
Other Study ID Numbers: LUV
First Submitted: January 16, 2007
First Posted: January 18, 2007
Results First Submitted: October 17, 2012
Results First Posted: March 4, 2016
Last Update Posted: March 4, 2016